ACBI3

ACBI3
Identifiers
IUPAC name
  • (2S,4R)-1-[(2S)-2-[4-[4-[(3S)-4-[4-[5-[(4S)-2-amino-3-cyano-4-methyl-6,7-dihydro-5H-1-benzothiophen-4-yl]-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]-3-methyl-1,4-diazepan-1-yl]butoxy]triazol-1-yl]-3-methylbutanoyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC50H62N14O6S2
Molar mass1019.26 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H]1CN(CCCN1C2=NC=CC(=N2)C3=NOC(=N3)[C@]4(CCCC5=C4C(=C(S5)N)C#N)C)CCCCOC6=CN(N=N6)[C@@H](C(C)C)C(=O)N7C[C@@H](C[C@H]7C(=O)N[C@@H](CO)C8=CC=C(C=C8)C9=C(N=CS9)C)O
InChI
  • InChI=1S/C50H62N14O6S2/c1-29(2)42(47(68)63-25-34(66)22-38(63)46(67)55-37(27-65)32-11-13-33(14-12-32)43-31(4)54-28-71-43)64-26-40(58-60-64)69-21-7-6-18-61-19-9-20-62(30(3)24-61)49-53-17-15-36(56-49)45-57-48(70-59-45)50(5)16-8-10-39-41(50)35(23-51)44(52)72-39/h11-15,17,26,28-30,34,37-38,42,65-66H,6-10,16,18-22,24-25,27,52H2,1-5H3,(H,55,67)/t30-,34+,37-,38-,42-,50-/m0/s1
  • Key:DQRZNYPHOWVXPQ-YDUPODKQSA-N

ACBI3 is an experimental anticancer drug which is one of the first examples of a proteolysis targeting chimera (PROTAC) against the protein KRAS.

Being a PROTAC, it is a bifunctional molecule with two halves joined by a linker; one half binds to its target, KRAS which is a key driver in certain types of cancer, while the other half binds E3 ligase which triggers the cell's natural protein degradation mechanisms. This causes the KRAS protein to be degraded.

In early stage testing, it was able to target 13 of the 17 most common mutated forms of KRAS found in cancer cells, allowing selective targeting of a wide range of cancer types. While this particular molecule is still at an early developmental stage, it is an important proof of concept that KRAS can be targeted with a PROTAC.[1][2][3][4]

See also

References

  1. ↑ Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M, et al. (September 2024). "Targeting cancer with small-molecule pan-KRAS degraders". Science. 385 (6715). New York, N.Y.: 1338–1347. Bibcode:2024Sci...385.1338P. doi:10.1126/science.adm8684. PMID 39298590.
  2. ↑ Hamilton G, Eggerstorfer MT, Stickler S (2024). "Development of PROTACS degrading KRAS and SOS1". Oncology Research. 32 (8): 1257–1264. doi:10.32604/or.2024.051653. PMC 11267056. PMID 39055890.
  3. ↑ Kumar H, Sobhia ME (August 2024). "Interplay of PROTAC Complex Dynamics for Undruggable Targets: Insights into Ternary Complex Behavior and Linker Design". ACS Medicinal Chemistry Letters. 15 (8): 1306–1318. doi:10.1021/acsmedchemlett.4c00189. PMC 11317996. PMID 39140051.
  4. ↑ Li Y, Yang L, Li X, Zhang X (August 2024). "Inhibition of GTPase KRASG12D: a review of patent literature". Expert Opinion on Therapeutic Patents. 34 (8): 701–721. doi:10.1080/13543776.2024.2369630. PMID 38884569.
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.